Immuno-Oncology and Immuno-Inflammation - Breakthrough Immuno-Science for Patients OSE Immunotherapeutics, a biotech dedicated to developing first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). • Tedopi® (therapeutic cancer vaccine): Registration Phase 3 in 2nd-line NSCLC in HLA-A2+ patients with secondary resistance. Phase 2 trials, sponsored by onco groups, of Tedopi® in combo in solid tumors. • Lusvertikimab (mAb IL-7R antagonist); Positive Phase 2 in UC; preclinical research in ALL. • OSE-279 (anti-PD1): 1st positive results in Phase 1/2 in solid tumors. • FR-104/VEL-101 (anti-CD28 mAb): developed in partnership with Veloxis in transplant; Phase 1/2 in renal transplant (CHU Nantes); successful Phase …

60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseases Tridek-One is a spin-off from Inserm that develops first-in-class therapeutic agonistic monoclonal antibodies targeting immune checkpoint inhibitory receptors for the treatment of autoimmune and inflammatory diseases. The company primarily focuses on the research and development of first-in-class anti-CD31 agonistic modalities designed to restore the immune balance. Anti-CD31 agonistic mAbs have the potential to provide targeted immunomodulatory activity with a favorable safety profile in diseases with high unmet clinical need. Tridek-One has initiated a discovery program which targets another ITIM receptor, fully leveraging its understanding of inhibitory checkpoint receptor …

14 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Discovery of novel immune checkpoint inhibitors for cancer immunotherapy OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. The company was incepted in 2010 and is managed by Jeremy Bastid, CEO and Gilles Alberici, President. The science at OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our in vivo screening approach aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Our lead asset, an anti-CD39 monoclonal antibody, has been out-licensed to Innate (2016) Pharma and then partnered …

69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Rebalancing the immune system, resolving inflammation. Drug candidates from our molecular platforms normalize the immune system by downregulating pro-inflammatory immune response and upregulating regulatory immune response. IMD-Pharma S.A.S is a french biotechnology company conducting research and development of innovative drug candidates for immune-related inflammatory diseases. Founded in 2016, IMD-Pharma is a company from the Laboratoire de Chimie de Coordination (CNRS) and the Centre de Physiopathologie de Toulouse Purpan (INSERM/CNRS/Université Toulouse III). immuno-modulation, anti-inflammatory drugs, chronic inflammatory diseases, Multiple Sclerosis, Rheumatoid Arthritis, dendrimers, monocyte rehabilitation, and psoriasis

49 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Blue Bees Therapeutics develops immunomodulatory proteins with therapeutic potential to fight cancer Blue Bees Therapeutics is a biotechnology company founded in March 2022, dedicated to the development of first-in-class immunotherapies for the treatment of cancers, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, within the Department of Pharmacology and Immunoanalysis from CEA Paris-Saclay. This technology allows to generate antibodies stimulating the anti-tumor immune response via a double cell receptor targeting coupled with heparan sulphate proteoglycans (HSPG). Immunothérapie, Immuno-oncologie, pharma, Biotech, Immunologie, Oncologie, Cancer, Médicament, and Drug

176 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Apmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies. Apmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies. Our innovative technological approach is to target tumors overexpressing matricellular protein thrombospondin-1 (TSP-1). Our long-term vision is to develop personalized immunotherapy approaches combining a proprietary therapeutic peptide targeting TSP-1 (namely TAX2 peptide) and a companion diagnostic kit, which may enable patient stratification for TAX2 therapy eligibility based on the monitoring of circulating TSP-1. immunologie and oncologie

29 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unique know-how to discover and engineer novel antibody therapeutics in immunology & inflammation (I&I) and neurology. Mabylon AG, a private Swiss biotech company, is leading innovation in antibody-based treatments for severe allergies, inflammation, and neurological disorders. Our B-cell screening platform rapidly identifies natural human antibodies with high specificity and therapeutic potential. MY006, our first-in-class multispecific antibody therapeutic for peanut allergy, is tackling the growing food allergy market.

47 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Leveraging science and innovation to accelerate the development of next-generation antibody therapeutics. AAX Biotech AB is a biotech company spun out from Karolinska Institutet by co-founders Mats AA Persson and Daniel X Johansson. We specialize in next-generation antibody therapeutics through our two unique and proprietary technologies, SeqitopeTM and Opti-mAbTM, that enable high-resolution and high throughput epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Our team is made up of highly qualified experts, all with PhDs in relevant fields. Our mission is to innovate and solve unmet needs …

76 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Actor of change Immune Biosolutions is a clinical-stage biotechnology company specializing in the discovery and engineering of avian and human antibodies for therapeutic applications. Utilizing cutting-edge technologies, we develop custom immunotherapeutic agents. Our discovery platform efficiently targets complex proteins and generate powerful, specific, and innovative antibodies. Additionally, our antibody production capability allows us to advance our own discovery programs in cancer and autoimmune diseases into the early phases of clinical development. Anticorps, Custom antibody development, Antibody, Développement sur mesure de génération d'anticorps, IgY, Chicken, Poulet, ELISA, Therapeutic Antibodies, Recombinant Antibodies, Humanized Antibodies, GPCRs, and Oncology

94 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our R&D platform is focused on developing immune modulating therapeutics for patients with autoimmune diseases. Our immune checkpoint activators protect patient’s organ tissue. Unique approach : - Potential for BEST-in-class super agonist against immune-mediated tissue damage - High selectivity for active T-cells - Proof of concept in relevant human in vitro models and mouse model of disease

66 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Interventional Immuno-Oncology Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently developing its first asset, the immune-modulating proprietary carbohydrate polymer IP-001 for the treatment of solid tumor cancers. IP-001 has unique physio-chemical and immunological properties that allows it to ignite a systemically active cancer immunotherapy from a routine tumor ablation; a minimal invasive intervention that destroys tumors and in doing so liberates tumor antigens. IP-001 enhances interactions of tumor antigens with the immune system, improves the motility of tumor infiltrating T cells, promotes their …

70 similar entities Type: Startup Activities: biotech deeptech legaltech Technologies: Synthetic Biology

Your partner in immunology projects! ImmunXperts a Q2 Solutions Company, your partner for what’s next in assay and biomarker development, advanced laboratory testing, and translational immunology. ImmunXperts brings an unrivaled ability to efficiently develop immunogenicity and immuno-oncology in vitro assays – to address both wanted and unwanted immunity for novel modalities. Immunogenicity Assessment, Immune Academy, Training, Consultancy, immuno-oncology, Cell Therapy, In vitro, assay development, Primary cells, Immunogenicity, and Immunology

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology